Theratechnologies Net debt/EBITDA
Was ist das Net debt/EBITDA von Theratechnologies?
Net debt/EBITDA von Theratechnologies, Inc. ist -4.31
Was ist die Definition von Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA von Unternehmen in Health Care Sektor auf TSX im Vergleich zu Theratechnologies
Was macht Theratechnologies?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Unternehmen mit net debt/ebitda ähnlich Theratechnologies
- Castor Maritime hat Net debt/EBITDA von -4.32
- BigCommerce hat Net debt/EBITDA von -4.32
- EVS Broadcast Equipment S.A hat Net debt/EBITDA von -4.32
- Global Indemnity hat Net debt/EBITDA von -4.31
- Align Technology hat Net debt/EBITDA von -4.31
- TG Therapeutics Inc hat Net debt/EBITDA von -4.31
- Theratechnologies hat Net debt/EBITDA von -4.31
- Natus Medical Inc hat Net debt/EBITDA von -4.31
- Telefonaktiebolaget LM Ericsson (publ) hat Net debt/EBITDA von -4.30
- Morris hat Net debt/EBITDA von -4.30
- Ortho Regenerative Technologies hat Net debt/EBITDA von -4.30
- Marine Products Corp hat Net debt/EBITDA von -4.30
- Ramsdens PLC hat Net debt/EBITDA von -4.30